Hussain Ali Almohammed

Dr. Hussain Ali Almohammed


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
HAHind Alnajashi
Hind Alnajashi
HAHussain Ali Almohammed
Hussain Ali Almohammed
AMAhmed Salah Morad
Ahmed Salah Morad
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
AAAbdullah Ahmed Albesher
Abdullah Ahmed Albesher
Introduction: Magnetic resonance imaging (MRI) is essential for diagnosing neuro-Behçet’s disease (NBD). The classic MRI sign typically results from parenchymal NBD lesions in the thalamus, midbrain, and the internal capsule. It may also affect the spinal cord, bilateral basal ganglia, pons, and white matter. Despite its importance, a comprehensive quantitative synthesis of MRI characteristics differentiating NBD subtypes is still needed. This study aimed to compare specific MRI findings, such as brainstem atrophy, enhancing lesions, and anatomical distribution, in acute and chronic progressive parenchymal NBD, with potential implications for prognosis and long-term disease management. Methods: This systematic review and meta-analysis was conducted according to the PRISMA 2020 guidelines. PubMed, Web of Science, and Scopus were searched from inception to August 2025. Retrospective studies assessing the MRI findings of parenchymal NBD were included. Results: Seven retrospective studies (total n = 327) with parenchymal NBD met the inclusion criteria. The characteristic lesions showed that brainstem atrophy was significantly less in the acute NBD group than in the chronic progressive NBD group (OR = 0.03, 95% CI [0.01, 0.11], p < 0.00001). Contrast-enhancing lesions were significantly more frequent in acute parenchymal NBD, consistent with active inflammatory disease (OR = 2.58, 95% CI [1.04, 6.40], p = 0.04). However, the anatomical distribution of MRI lesions does not differ significantly between acute and chronic progressive NBD. No significant difference was observed between the mild-to-moderate and severe groups in the brainstem (OR = 0.42, p = 0.22) and thalamus (OR = 0.31, p = 0.12). Conclusion: Our analysis provides quantitative evidence for distinct MRI characteristics, such as differential brainstem atrophy and enhanced lesion incidence, which may inform NBD subtyping and have implications for prognosis and long-term disease management. However, this meta-analysis is limited by the retrospective nature of the included studies and their potential heterogeneity, necessitating further prospective research to confirm these findings. Systematic review registration: PROSPERO, CRD420251178483.

19 December 2025 in BMC Neurology
Verified
Journal Article
Open access
HAHind Alnajashi
Hind Alnajashi
HAHussain Ali Almohammed
Hussain Ali Almohammed
AMAhmed Salah Morad
Ahmed Salah Morad
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
TKTanveer Nidal Khan
Tanveer Nidal Khan
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system through persistent inflammation and demyelination. Cladribine, an immunosuppressive agent, has emerged as a promising high-efficacy disease-modifying therapy. However, concerns remain regarding its long-term safety, particularly the risks of lymphopenia, infections, and malignancy. This study aimed to evaluate the efficacy and safety of oral cladribine, including a control group defined by placebo, fingolimod, and natalizumab, by analyzing the impact of cladribine on the annualized relapse rate, relapse-free rate, expanded disability status, and adverse outcomes, such as malignancy, infections, and persistent lymphopenia. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. The databases PubMed, Web of Science, and Google Scholar were comprehensively searched to identify randomized controlled trials and observational studies comparing oral cladribine with other MS treatments or placebo. This study included 24,976 patients with MS. Cladribine significantly reduced annualized relapse rates (mean difference [MD] = - 0.09; P = 0.0004), especially versus placebo (MD = - 0.15; P = 0.0002). No overall difference in Expanded Disability Status Scale was identified, although fingolimod showed better post-treatment outcomes (MD = 0.40; P < 0.00001). Relapse-free rates were similar, except in the placebo subgroup favoring cladribine (MD = 2.46; P < 0.00001). Cladribine was associated with an increased risk of persistent lymphopenia (odds ratio [OR] = 20.20; P < 0.00001), whereas infection (OR = 1.18; P = 0.78) and malignancy rates (OR = 1.87; P = 0.63) were comparable to those of the controls. The interpretation was limited by study heterogeneity and the absence of a pooled analysis of several secondary outcomes. Cladribine may be a valuable therapeutic option for relapsing-remitting MS with a strong efficacy profile. The lymphopenia incidence highlights the need for regular hematological monitoring to ensure the safety of cladribine.

19 July 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
NANibras Alkhamis
Nibras Alkhamis
HAHussain Ali Almohammed
Hussain Ali Almohammed
TKTanveer Nidal Khan
Tanveer Nidal Khan
JAJory Hamoud Alzahrani
Jory Hamoud Alzahrani
LALama A. Alsalboud
Lama A. Alsalboud
SASaud Alnaaim
Saud Alnaaim
Background: Atrial fibrillation (AF) is a common but frequently undiagnosed cause of ischemic stroke, particularly among patients with cryptogenic stroke and embolic stroke of undetermined source (ESUS). Implantable cardiac monitors (ICMs) enable prolonged continuous rhythm monitoring and may improve AF detection following ischemic stroke or transient ischemic attack (TIA). This systematic review and meta-analysis aimed to evaluate the diagnostic yield, clinical impact, and safety of prolonged ICM monitoring in patients with ischemic stroke or TIA. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered with PROSPERO (CRD42024573913). PubMed, Google Scholar, and the Cochrane Library were systematically searched. Randomized controlled trials and observational studies evaluating the use of ICMs after ischemic stroke or TIA were included. Randomized evidence was synthesized narratively, whereas single-arm random-effects meta-analyses of observational studies were performed to estimate pooled proportions for AF detection, oral anticoagulation initiation, recurrent ischemic stroke or TIA, and device-related adverse events. Results: Twelve completed studies involving 4563 participants met the inclusion criteria, including two randomized controlled trials and ten observational studies. One additional ongoing randomized controlled trial (Find-AF 2) involving a planned enrollment of 5200 participants was identified and is described narratively. Across the observational studies, the pooled AF detection rate during prolonged ICM monitoring was 25.9% (95% CI, 18.9–33.5%), although substantial heterogeneity was observed (I2 = 95%). Oral anticoagulation was initiated in 94.2% (95% CI, 79.4–100.0%) of patients diagnosed with AF. Device-related complications were uncommon, with a pooled incidence of 3.7% (95% CI, 2.0–6.0%; I2 = 0%), while the pooled rate of recurrent ischemic stroke or TIA during follow-up was 6.2% (95% CI, 3.9–9.2%). Narrative synthesis of the randomized evidence demonstrated that ICMs significantly increased AF detection compared with conventional monitoring but did not demonstrate a significant reduction in recurrent stroke during the available follow-up period. Conclusions: Prolonged implantable cardiac monitoring identifies AF in approximately one-quarter of patients following ischemic stroke or TIA and frequently leads to the initiation of oral anticoagulation, with a favorable safety profile. Although ICMs substantially improve AF detection, current evidence remains insufficient to confirm that increased detection translates into a reduction in recurrent stroke. Large, adequately powered randomized controlled trials are needed to determine the long-term clinical benefits of ICM-guided management and to define the optimal monitoring strategy for patients following ischemic stroke.

17 September 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
AAAbdullah M Alkutbi
Abdullah M Alkutbi
HAHussain Ali Almohammed
Hussain Ali Almohammed
AMAhmed Salah Morad
Ahmed Salah Morad
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
LGLamyaa Gharawi
Lamyaa Gharawi
Background: Multiple trials have evaluated the benefits of endovascular thrombectomy (EVT) in patients with large-core ischemic stroke. This study aimed to determine the efficacy and safety of EVT compared with medical management (MM) alone in patients with large ischemic core infarcts. Methods: This study was registered in PROSPERO (CRD420261360129). A comprehensive search of PubMed, Web of Science, and the Cochrane Library was conducted to identify all relevant studies published up to April 2026. Effect sizes were calculated as risk ratios (RRs) using random-effects or fixed-effects models, as appropriate. Study quality was assessed using the Cochrane Risk of Bias tool and the Newcastle–Ottawa Scale. Subgroup and sensitivity analyses were performed to explore heterogeneity and evaluate outcomes across different patient populations. Outcomes assessed included excellent functional independence (mRS 0–2) and favorable functional outcome (mRS 0–3) at 3 months, mean mRS at 3 and 12 months, symptomatic intracranial hemorrhage, and all-cause mortality at 3 and 12 months. Results: Nine eligible studies (5 randomized controlled trials [RCTs] and 4 cohort studies; total sample size = 2252) were included to evaluate the comparative efficacy and safety of EVT versus MM alone in patients with acute ischemic stroke (AIS) secondary to large vessel occlusion. Our pooled analysis demonstrated a significantly higher rate of achieving a modified Rankin Scale (mRS) score of 0–2 in the EVT group compared with the MM group (RR = 2.64, 95% CI [1.79–3.90], p < 0.00001). Similarly, the likelihood of achieving an mRS score of 0–3 was significantly greater with EVT than with MM (RR = 1.78, 95% CI [1.40–2.26], p < 0.00001). The mean mRS score at 3 months was also significantly lower in the EVT group (MD = −0.58, 95% CI [−0.77 to −0.39], p < 0.00001). Safety outcomes were comparable between groups, with no significant differences in the rates of symptomatic intracranial hemorrhage (sICH) (RR = 1.36, 95% CI [0.88–2.11], p = 0.17) or mortality (RR = 0.96, 95% CI [0.65, 1.42], p = 0.84, I2 = 75%). Conclusions: Our findings suggest that EVT is associated with improved functional outcomes compared with MM alone, particularly in evidence derived from RCTs, while maintaining an acceptable safety profile. Further high-quality RCTs are warranted to strengthen the evidence base and validate these findings.

3 August 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
HAHussain Ali Almohammed
Hussain Ali Almohammed
HTHusna Irfan Thalib
Husna Irfan Thalib
SKSamiya Khanam
Samiya Khanam
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
WAWejdan Ahmed
Wejdan Ahmed
AAAlia Alokley
Alia Alokley
Background and objectives: Cerebrovascular strokes and transient ischemic attacks (TIAs) remain leading causes of global mortality and long-term disability. Emerging evidence suggests that pre-existing structural brain frailty—driven by chronic cerebral small vessel disease (CSVD)—critically limits neuroplastic compensation and determines overall recovery potential. This systematic review aims to synthesize current evidence evaluating brain frailty as an independent determinant of functional and cognitive outcomes. Methods: Following PRISMA and Cochrane SWiM guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, Embase, and Scopus. Methodological quality was evaluated using the Newcastle–Ottawa Scale (NOS). Due to anticipated clinical and methodological heterogeneity, data were synthesized via a structured narrative approach. A total of 15 studies comprising more than 18,000 participants met the inclusion criteria, including prospective cohorts, retrospective cohorts, registry analyses, pooled cohort studies, and post hoc analyses of randomized controlled trials. Results: Structural disconnection burden emerged as one of the strongest predictors of post-stroke cognitive impairment, demonstrating remarkably large effect sizes at both 6 months (OR 9.96, 95% CI 2.21–52.40) and 36 months (OR 12.27, 95% CI 2.80–63.40). Additionally, blood–brain barrier (BBB) leakage was significantly associated with longitudinal cognitive decline (β −3.62 to −0.16, p < 0.001). Pre-existing brain frailty was also consistently associated with poorer functional recovery following acute ischemic stroke, even among patients undergoing advanced reperfusion strategies such as endovascular thrombectomy or intravenous thrombolysis. Conclusions: Brain frailty should be integrated into clinical prognostic frameworks as a key marker for predicting long-term cognitive function and functional independence in stroke patients. However, the substantial methodological and clinical heterogeneity observed across the included literature must be acknowledged as a key limitation of the current evidence base. Large-scale, prospective, multicenter longitudinal studies are required to better standardize brain frailty metrics and validate their utility in clinical practice.